期刊文献+

我国药品低可负担性原因分析 被引量:2

An Analysis of the Low Affordability of Medicines and Drugs in China
下载PDF
导出
摘要 我国药品可负担性低主要表现在药品费用高,患者自付比例增长过快。我国药品可负担性低的原因主要有药品价格高、用量多和可替代性等。其中,药品价格高的主要原因是进口药品、合资药品价格高,部分国产"新药"定价虚高等;人口增长,人口老龄化和健康意识提高促进药品使用量上升,医疗保障制度下供需双方的道德风险致使药品使用量增加成为药品费用居高不下主要原因;此外还有药品可替代性的影响。 The low affordability of medicines and drugs in China is mainly reflected in their high prices and the fast increasing proportion of expenditure from patients themselves. The major reasons for the low affordability are the high priced imported medicines and drugs, brand medicines and drugs produced by joint-ventures, and overpriced "new medicines and drugs" produced by domestic pharmaceutical manufacturers. Other reasons such as the increasing population, the aging of the population, the increasing health consciousness among citizens that promotes medication consumption, and the moral risk caused by the current health insurance system which boosts medicine consumption that are all contribumble to the stable high medicine prices in China; Additionally, medicine substitutability is also an influencing factor to high medicine prices.
出处 《医学与社会》 2009年第2期22-24,共3页 Medicine and Society
关键词 药品 可负担性 原因 Medicines And Drugs Affordability Reasons
  • 相关文献

参考文献4

二级参考文献15

  • 1廖继洲.诊所与地区医院药品用量排序总览[M].台北:-,1997.2. 被引量:1
  • 2Berndt ER. Pharmaceuticals in U.S. health care determinants of quantity, and price[J]. Journal of Economic Perspectives, 2002,16 (4): 45-66. 被引量:1
  • 3Kremer M. Pharmaceuticals and the developing world[J]. Journal of Economic Perspectives, 2002, 16(4): 67-90. 被引量:1
  • 4Levit K, Smith C. Health spending rebound continues in 2002[J]. Health Affairs, 2004, 23(1): 147-159. 被引量:1
  • 5Mrazek MF. Comparative approaches to pharmaceutical price regulation in the european union[J]. Croatian Medical Journal, 2002, 43(4): 453-61. 被引量:1
  • 6Bloor K, Maynard A, Freemantle N. Lessons form international experience in controlling pharmaceutical expenditure[J]. British Medical Journal, 1996, 312(7 045): 1 525. 被引量:1
  • 7Giovanni G. The german experience in reference pricing[J]. Health Policy, 1998(44): 73-85. 被引量:1
  • 8Addis A, Magrini N. New approaches toanalyzing prescription data and transfer pharmacoepidemiological and evidence-based reports to prescriberes[J]. Pharmacoepidemiology and Drug Safety, 2002(11)- 721-726. 被引量:1
  • 9The Kaiser Family Foundation. Prescription drug trends: a chartbook update[R]. 2001. 被引量:1
  • 10Heftier S. Health spending growth up in 1999, Faster growth expected in the future[J]. Health Affairs, 2001, 20(2): 193-203. 被引量:1

共引文献30

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部